Circulating CD14⁺⁺CD16⁺ Monocyte Subsets as a Surrogate Marker of the Therapeutic Effect of Corticosteroid Therapy in Patients With Cardiac Sarcoidosis

• Orii Makoto

  Department of Cardiovascular Medicine, Wakayama Medical University

• Imanishi Toshio

  Department of Cardiovascular Medicine, Wakayama Medical University

• Teraguchi Ikuko

  Department of Cardiovascular Medicine, Wakayama Medical University

• Nishiguchi Tsuyoshi

  Department of Cardiovascular Medicine, Wakayama Medical University

• Shiono Yasutsugu

  Department of Cardiovascular Medicine, Wakayama Medical University

• Yamano Takashi

  Department of Cardiovascular Medicine, Wakayama Medical University

• Ino Yasushi

  Department of Cardiovascular Medicine, Wakayama Medical University

• Hirata Kumiko

  Department of Cardiovascular Medicine, Wakayama Medical University

• Kubo Takashi

  Department of Cardiovascular Medicine, Wakayama Medical University

• Tanaka Atsushi

  Department of Cardiovascular Medicine, Wakayama Medical University

• Akasaka Takashi

  Department of Cardiovascular Medicine, Wakayama Medical University

Bibliographic Information

Other Title

• Circulating CD14⁺⁺CD16⁺ Monocyte Subsets as a Surrogate Marker of the Therapeutic Effect of Corticosteroid Therapy in Patients With Cardiac Sarcoidosis

Abstract

Background:We aimed to evaluate whether specific monocyte subsets could serve as surrogate markers of disease activity in cardiac sarcoidosis (CS) evaluated by ¹⁸F-fluoro-2-deoxyglucose positron emission tomography (¹⁸F-FDG PET).Methods and Results:We studied 28 patients with CS (8 men; mean age: 61±9 years) diagnosed according to consensus criteria. We divided the patients into 2 groups: known CS receiving corticosteroid therapy (Rx(+); n=13) and new-onset CS (Rx(−); n=15), and analyzed 3 distinct monocyte subsets (CD14⁺CD16⁻, CD14⁺⁺CD16⁺, and CD14⁺⁻CD16⁺). Monocyte subsets were also analyzed in 10 Rx(−) patients before and 12 weeks after starting corticosteroid therapy. Inflammatory activity was quantified by ¹⁸F-FDG PET using the coefficient of variation (COV) of the standardized uptake value (SUV). The proportion of CD14⁺⁺CD16⁺monocytes in Rx(+) patients (10.8 [0.2–23.5] %) was significantly lower than in Rx(−) patients (23.0 [11.5–38.4] %, P=0.001). After corticosteroid therapy, the COV of the SUV was significantly improved from 0.32 [0.14–0.62] to 0.17 [0.04–0.43] (P=0.017). The proportion of CD14⁺⁺16⁺monocytes showed a significant decrease from 22.2 [8.8–38.4] % to 8.4 [1.8–16.8] % (P=0.001). The decrease in the proportion of CD14⁺⁺16⁺monocytes significantly correlated with the decrease in the COV of the SUV (r=0.495, P=0.027).Conclusions:CD14⁺⁺16⁺monocytes are a possible surrogate marker of the therapeutic effect of corticosteroid therapy in CS. (Circ J 2015; 79: 1585–1592)

Journal

• Circulation Journal

  Circulation Journal 79 (7), 1585-1592, 2015

  The Japanese Circulation Society

Keywords

• Cardiac sarcoidosis
• CD14⁺⁺16⁺ monocytes
• ¹⁸F-fluoro-2-deoxyglucose
• Positron emission tomography

Details

• CRID: 1390001205106918912
• NII Article ID: 130005083931
• NII Book ID: AA11591968
• DOI: 10.1253/circj.cj-14-1422
• ISSN: 13474820
• ISSN: 13469843
• NDL BIB ID: 026523728
• PubMed: 25833081
• Web Site: https://ndlsearch.ndl.go.jp/books/R000000004-I026523728
• Web Site: https://www.jstage.jst.go.jp/article/circj/79/7/79_CJ-14-1422/_pdf
• Web Site: https://search.jamas.or.jp/link/ui/2015335499
• Text Lang: en
• Data Source:
  • JaLC
  • NDL
  • Crossref
  • PubMed
  • CiNii Articles
  • KAKEN
• Abstract License Flag: Disallowed